(Unaudited)
For the three months For the nine months
(Thousands of ended: ended:
Canadian dollars, Sept. 30, Sept. 30, Sept. 30, Sept. 30,
except share and 2008 2007 2008 2007
per share amounts) $ $ $ $
-------------------------------------------------------------------------
REVENUE
Product sales 3,863 2,818 9,880 10,359
Licensing 5,576 1,058 7,701 4,786
Research and development
collaborations - 1,217 - 1,217
-------------------------------------------------------------------------
9,439 5,093 17,581 16,362
-------------------------------------------------------------------------
EXPENSES
Cost of goods sold
(excluding depreciation) 1,755 1,012 4,389 6,716
Research and development, net 6,267 7,145 18,264 17,296
Selling, general and
administrative 4,888 4,622 15,766 15,840
Financial costs 733 434 2,153 1,474
Impairment loss on
long-term investment 400 874 1,091 874
Depreciation and amortization 536 510 1,585 1,482
Interest income (351) (810) (1,554) (2,707)
Foreign exchange loss (gain) 488 (107) 196 280
-------------------------------------------------------------------------
14,716 13,680 41,890 41,255
-------------------------------------------
'/>"/>
| SOURCE Labopharm Inc. Copyright©2008 PR Newswire. All rights reserved |